Pulse of Healing: A Non-Invasive Ultrasound Solution for Managing Inflammation in Psoriasis

Psoriasis is a chronic, immune-mediated skin disease that significantly reduces quality of life and places a substantial burden on the NHS. Current treatments—including biologics and systemic therapies—are often expensive, require long-term use, and can cause serious side effects. There is a clear unmet need for non-invasive, safe, and accessible therapies that are suitable for long-term home use. This project aims to develop and clinically validate a novel, wearable, ultrasound-based therapeutic system that modulates inflammatory pathways in people living with psoriasis. The device delivers low-intensity pulsed ultrasound within FDA/MHRA-defined safety thresholds to non-invasively stimulate systemic anti-inflammatory effects. Preclinical and early ex vivo studies have demonstrated relevant biological activity, supporting the feasibility of this approach. Our multidisciplinary team brings together expertise in bioengineering, dermatology, inflammation biology, and patient engagement. We are conducting a proof-of-concept study to identify ultrasound parameters that drive the most effective immunological response. Funding from i4i Connect will support the development of a refined wearable device and bring it to near-clinical readiness. This will enable self-administered, at-home treatment—reducing the burden on patients, healthcare professionals, and NHS resources. We will deliver three integrated work packages aligned with our phased development plan: 1) Early usability studies): We will conduct structured testing of the early-stage prototype with people living with psoriasis, focusing on comfort, tolerability, and ease of use in simulated home environments. A critical technical goal is validating device placement between the ribs to ensure effective targeting of the spleen while avoiding interference from bone. Insights will directly inform the design of a long-term wearable solution. 2) Device development and technical optimisation: Findings from Phase 1 will guide the creation of a refined, functional MVP. This will include finalising materials, electronics, and ergonomic specifications. A mechanical engineer and hardware lead will join the team to ensure clinical robustness and regulatory readiness. 3)Route-to-market and business model assessment: We will define our commercialisation strategy and model the device’s pricing strategy with a focus on NHS adoption. Engagement with dermatologists, UV therapy clinics, and NHS procurement stakeholders will help validate use cases and pathways. The International Federation of Psoriasis Associations (IFPA) will support dissemination and broader stakeholder engagement. This project represents a new frontier in non-pharmacological, at-home care for chronic inflammatory conditions and has the potential to shift the psoriasis treatment paradigm.